NEW YORK (GenomeWeb) – Roche said today that it has acquired the exclusive rights to next-generation sequencing target enrichment technology from AbVitro, a company focused on therapeutic target discovery.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.